Seeking to accelerate the process of getting new vaccines to market, PRA Health Sciences ($PRAH) partnered with the Alliance for Multispecialty Research (AMR) to look for ways to help vaccine studies run more efficiently and effectively. The deal joins a leading contract research organization and a clinical research network, allowing the two "to make significant strides in implementing efficient solutions to smarter vaccine development," AMR CEO Brenda Atchison said in a statement. Release